HS-IT101

Phase 1Biologic

TThe Affiliated Hospital of Qingdao University

HS-IT101 is one of 150 biologic programs targeting Advanced Solid Tumor. It is currently in Phase 1.

Indications

Total Trials

Active Trials

149

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Solid TumorNot yet recruiting

Advanced Solid TumorsRecruiting

Breast CancerNot yet recruiting

MelanomaEnrolling by invitation

Advanced Solid TumorPhase 1

Not yet recruiting

Advanced Solid TumorsPhase 1

Recruiting

Breast CancerPhase 1

Not yet recruiting

MelanomaPhase 1

Enrolling by invitation

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Lexiscan

Astellas

Preclinical

1 2

Voltaren

Novartis

Preclinical

1 3

Zolymbus

AbbVie

Preclinical

1 4

Blenoxane

Bristol-Myers Squibb

Preclinical

1 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 6

Duragesic-100

CCephalon

Preclinical

2 7

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 8

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 9

Tricor

JJagotec

Preclinical

1 10

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Not yet recruiting

Breast Cancer

NCT05505812

Phase 1Not yet recruiting

Advanced Solid Tumor

NCT05539768

Q1 2028

Phase 1Recruiting

Advanced Solid Tumors

NCT06342336

Clinical

Trials by Indication[1]

Breast Cancer1 trial

Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Breast Cancer

Not yet recruiting·TThe Affiliated Hospital of Qingdao University·Phase 1·NCT05505812·10 enrolled

Melanoma1 trial

HS-IT101 Injection in the Treatment of Advanced Melanoma

Enrolling by invitation·QQingdao Sino-Cell Biomedicine Co., Ltd.·Phase 1·NCT06941818·10 enrolled

Advanced Solid Tumors1 trial

HS-IT101 Injection in the Treatment of Advanced Solid Tumors

Recruiting·QQingdao Sino-Cell Biomedicine Co., Ltd.·Phase 1·NCT06342336·44 enrolled

Advanced Solid Tumor1 trial

Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Solid Tumor

Not yet recruiting·TThe Affiliated Hospital of Qingdao University·Phase 1·NCT05539768·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for HS-IT101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HS-IT101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HS-IT101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Affiliated Hospital of Qingdao University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: TThe Affiliated Hospital of Qingdao University

HS-IT101

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q1 2028

Trials by Indication[1]

Breast Cancer1 trial

Melanoma1 trial

Advanced Solid Tumors1 trial

Advanced Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News